NRSN ▲ +9.5% - NeuroSense Therapeutics Ltd. $NRSN NRSN - NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS NeuroSense Therapeutics shares climbed 9.5% following the company's announcement of an accelerated, capital-efficient strategy to push its PrimeC treatment closer to regulatory approval for ALS (amyotrophic lateral sclerosis). The new approach appears to have resonated with investors as a positive signal that the company has identified a more efficient path forward for one of its key clinical programs. The rally suggests the market views this strategic refinement as improving the likelihood and timeline for PrimeC's potential approval. 31-AUG-2026 08:45 AM ET